Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Ferrara, 2006, Pathophysiology of graft-versus-host disease, Semin. Hematol., 43, 3, 10.1053/j.seminhematol.2005.09.001 Dykewicz, 2001, Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients, Clin. Infect. Dis., 33, 139, 10.1086/321805 Coiffier, 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N. Engl. J. Med., 346, 235, 10.1056/NEJMoa011795 Jin, 2009, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells, Cell Stem Cell, 5, 31, 10.1016/j.stem.2009.04.018 Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia, N. Engl. J. Med., 376, 836, 10.1056/NEJMoa1609783 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N. Engl. J. Med., 378, 449, 10.1056/NEJMoa1709919 Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N. Engl. J. Med., 377, 2545, 10.1056/NEJMoa1708566 Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222 Bach, 2017, FDA Approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug, JAMA, 318, 1861, 10.1001/jama.2017.15218 Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J. Clin. Invest., 126, 2123, 10.1172/JCI85309 Locke, 2017, Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma, Mol. Ther., 25, 285, 10.1016/j.ymthe.2016.10.020 Grupp, 2016, Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL), Blood, 128, 221, 10.1182/blood.V128.22.221.221 DeFrancesco, 2017, CAR-T’s forge ahead, despite Juno deaths, Nat. Biotechnol., 35, 6, 10.1038/nbt0117-6b Venkataraman, 2011, Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders, Am. J. Clin. Pathol., 136, 625, 10.1309/AJCPKUM9J4IXCWEU Fromm, 2011, Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma, Cytometry B Clin. Cytom., 80, 91, 10.1002/cyto.b.20561 Chaperot, 2001, Identification of a leukemic counterpart of the plasmacytoid dendritic cells, Blood, 97, 3210, 10.1182/blood.V97.10.3210 Del Giudice, 2004, The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes, Haematologica, 89, 303 Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J. Clin. Invest., 126, 3814, 10.1172/JCI87366 Ehninger, 2014, Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia, Blood Cancer J., 4, e218, 10.1038/bcj.2014.39 Taussig, 2005, Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia, Blood, 106, 4086, 10.1182/blood-2005-03-1072 Sato, 1993, Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells, Blood, 82, 752, 10.1182/blood.V82.3.752.752 Manz, 2002, Prospective isolation of human clonogenic common myeloid progenitors, Proc. Natl. Acad. Sci. USA, 99, 11872, 10.1073/pnas.172384399 Korpelainen, 1996, IL-3 receptor expression, regulation and function in cells of the vasculature, Immunol. Cell Biol., 74, 1, 10.1038/icb.1996.1 Brizzi, 1993, Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells, J. Clin. Invest., 91, 2887, 10.1172/JCI116534 Gill, 2014, Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells, Blood, 123, 2343, 10.1182/blood-2013-09-529537 Mardiros, 2013, T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia, Blood, 122, 3138, 10.1182/blood-2012-12-474056 Al-Hussaini, 2016, Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform, Blood, 127, 122, 10.1182/blood-2014-05-575704 Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J., 6, e458, 10.1038/bcj.2016.61 Bachmann, 2017, Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells, Oncotarget, 9, 7487, 10.18632/oncotarget.23556 Albert, 2017, A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform, OncoImmunology, 6, e1287246, 10.1080/2162402X.2017.1287246 Feldmann, 2017, Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”, Oncotarget, 8, 31368, 10.18632/oncotarget.15572 Mitwasi, 2017, Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells, Oncotarget, 8, 108584, 10.18632/oncotarget.21017 Pishali Bejestani, 2017, Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model, OncoImmunology, 6, e1342909, 10.1080/2162402X.2017.1342909 Mahnke, 2013, The who’s who of T-cell differentiation: human memory T-cell subsets, Eur. J. Immunol., 43, 2797, 10.1002/eji.201343751 Bonifant, 2016, CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia, Mol. Ther., 24, 1615, 10.1038/mt.2016.116 Mardiros, 2015, T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia, Curr. Opin. Hematol., 22, 484, 10.1097/MOH.0000000000000190 Budde, 2017, Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial, Blood, 130, 811, 10.1182/blood.V130.Suppl_1.811.811 Koristka, 2014, Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system, Blood, 124, 3494, 10.1182/blood.V124.21.3494.3494 Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol. Ther. Oncolytics, 3, 16011, 10.1038/mto.2016.11 Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat. Med., 3, 730, 10.1038/nm0797-730 Lapidot, 1994, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, 367, 645, 10.1038/367645a0 Hope, 2004, Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity, Nat. Immunol., 5, 738, 10.1038/ni1080 Jordan, 2000, The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells, Leukemia, 14, 1777, 10.1038/sj.leu.2401903 Blair, 1998, Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71−/HLA-DR−, Blood, 92, 4325, 10.1182/blood.V92.11.4325 Venton, 2016, Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors, Blood Cancer J., 6, e469, 10.1038/bcj.2016.78 Crews, 2016, RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML, Cell Stem Cell, 19, 599, 10.1016/j.stem.2016.08.003 Taussig, 2008, Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells, Blood, 112, 568, 10.1182/blood-2007-10-118331 Cox, 2004, Characterization of acute lymphoblastic leukemia progenitor cells, Blood, 104, 2919, 10.1182/blood-2004-03-0901 Tettamanti, 2013, Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor, Br. J. Haematol., 161, 389, 10.1111/bjh.12282 Pizzitola, 2014, Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo, Leukemia, 28, 1596, 10.1038/leu.2014.62 Tamada, 2012, Redirecting gene-modified T cells toward various cancer types using tagged antibodies, Clin. Cancer Res., 18, 6436, 10.1158/1078-0432.CCR-12-1449 Rodgers, 2016, Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies, Proc. Natl. Acad. Sci. USA, 113, E459, 10.1073/pnas.1524155113 Ma, 2016, Versatile strategy for controlling the specificity and activity of engineered T cells, Proc. Natl. Acad. Sci. USA, 113, E450, 10.1073/pnas.1524193113 Chichili, 2015, A CD3×CD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates, Sci. Transl. Med., 7, 289ra82, 10.1126/scitranslmed.aaa5693 Uy, 2019, Flotetuzumab, an investigational CD123 × CD3 bispecific Dart® protein, in salvage therapy for primary refractory and early relapsed acute myeloid leukemia (AML) patients, Blood, 134, 733, 10.1182/blood-2019-122073 Uy, 2018, Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific DART® protein in patients with relapsed/refractory acute myeloid leukemia (AML), Blood, 132, 764, 10.1182/blood-2018-99-117085 Nijmeijer, 2009, Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors, Exp. Hematol., 37, 376, 10.1016/j.exphem.2008.11.002 Koristka, 2013, Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B, J. Autoimmun., 42, 105, 10.1016/j.jaut.2013.01.002 Cartellieri, 2014, A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells, PLoS ONE, 9, e93745, 10.1371/journal.pone.0093745 Meinke, 1996, Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons, Mol. Cell. Biol., 16, 6937, 10.1128/MCB.16.12.6937